Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

MHLWRegulator guidanceBioequivalenceMedicinesHigh confidenceLast verified October 5, 2026

JP guideline for bioequivalence studies of generic products

Guideline for Bioequivalence Studies of Generic Products

Current edition

Partial revision of March 19, 2020 (English translation)

About this standard

Describes how to compare a generic product with the innovator product: reference product choice, study design, subjects, measurements, acceptance range, dissolution tests, reporting and dosage forms where a study is waived.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), NMPA Notice 2016 No. 61, Annex 3, FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube